Handelsbanken Fonder AB Takes $2.91 Million Position in Qiagen N.V. $QGEN

Handelsbanken Fonder AB acquired a new position in shares of Qiagen N.V. (NYSE:QGEN) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 74,401 shares of the company’s stock, valued at approximately $2,909,000.

A number of other large investors have also recently made changes to their positions in the company. Danske Bank A S purchased a new position in Qiagen in the third quarter worth approximately $36,000. Manchester Capital Management LLC purchased a new stake in shares of Qiagen in the 4th quarter valued at approximately $42,000. Global Retirement Partners LLC increased its position in shares of Qiagen by 279.9% in the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after purchasing an additional 851 shares during the last quarter. Hilltop National Bank acquired a new stake in shares of Qiagen in the 2nd quarter valued at $50,000. Finally, Advisory Services Network LLC acquired a new stake in shares of Qiagen in the 3rd quarter valued at $64,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Trading Down 0.0%

Shares of Qiagen stock opened at $42.94 on Monday. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. The company has a fifty day simple moving average of $40.09 and a 200-day simple moving average of $41.23. The stock has a market cap of $8.85 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 4.28 and a beta of 0.63. Qiagen N.V. has a 12-month low of $32.53 and a 12-month high of $57.81.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The firm had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. During the same period last year, the business earned $0.60 EPS. Qiagen’s revenue for the quarter was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, equities analysts forecast that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

QGEN has been the subject of several recent analyst reports. Stifel Nicolaus set a $40.00 price objective on shares of Qiagen in a research report on Friday, August 7th. Robert W. Baird set a $43.00 target price on Qiagen and gave the company an “outperform” rating in a report on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $43.00 price target on shares of Qiagen in a research note on Thursday, April 30th. Berenberg Bank set a $45.50 price target on Qiagen and gave the stock a “hold” rating in a report on Tuesday, July 14th. Finally, Zacks Research raised Qiagen from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $43.93.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.